The importance of treatment acceptability to patients

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue SUPPL. 1, 2000, Pages 25-34

  Naber, D ^a   Kasper, S ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b University Hospital for Psychiatry   (Austria)

Author keywords

Antipsychotics; EPS; Patient acceptability; Schizophrenia; Sexual dysfunction; Therapeutic alliance; Weight gain

Indexed keywords

NEUROLEPTIC AGENT;

AMENORRHEA; COST EFFECTIVENESS ANALYSIS; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; MENTAL DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; WEIGHT GAIN;

EID: 0034531088     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500050518497     Document Type: Review

References (110)

1. From noncompliance to collaboration in the treatment of schizophrenia
2. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
3. Psychosis: Insight and compliance
4. Patient satisfaction, compliance and outcome in schizophrenia; a synthesis
5. Relapse of psychiatric patients in foster care
6. Rehospitalization in chronic schizophrenia
7. Frequent rehospitalization and noncompliance with treatment
8. Twenty years' follow-up of first psychiatric presentation for schizophrenia: What could have been prevented?
9. Measurement of therapeutic response in schizophrenia. A critical survey
10. Quality-of-life issues in medicated schizophrenic patients
11. A two year prospective study of treatment compliance in patients with schizophrenia
12. An overview of patient satisfaction with psychiatric treatment
13. Does patient satisfaction correlate with success?
14. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation
15. The content and context of compliance
16. Which side-effects really matter to our patients?
17. Patients' satisfaction with antipsychotic drug therapy for schizophrenia
18. HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment
19. A prospective, multicenter study of patients' refusal of antipsychotic medication
20. Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: A multinational survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics
21. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
22. Clinical nonrecognition of neuroleptic-induced movement disorders: A cautionary study
23. Subjective response to antipsychotic drugs
24. EPS: Subjective and mental aspects and their impact on outcome
25. The many faces of akathisia
26. Suicide attempts with akathisia
27. Response to antipsychotic medication: The doctor's and the consumer's view
28. Compliance and outcome in patients treated with antipsychotics: The impact of extrapyramidal syndromes
29. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia
30. Depressive signs and symptoms of schizophrenia
31. Neurocognitive impairment in schizophrenia and how it affects treatment options
32. Relationship of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia
33. The side effects of antipsychotic drugs. 1. CNS and neuromuscular affects
34. Correlations between akathisia and residual psychopathology: A by-product of neuroleptic-induced dysphoria
35. Is neuroleptic dysphoria a healthy response?
36. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
37. Subjective response as a predictor of outcome in pharmacotherapy (The consumer has a point)
38. Subjective response to thiothixene and chlorpromazine
39. Spontaneous and drug-induced movement disorders in schizophrenia
40. The psychological impact of psychiatric admission: Some preliminary findings
41. Treatment outcome of first episode schizophrenia
42. Effective management of antipsychotic side-effects in early psychosis
43. Neuroleptics and sexual functioning
44. Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women
45. Do we know what matters to our patients?
46. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients
47. Schizophrenia and sexuality
48. Antipsychotic drug therapy and sexual dysfunction in men
49. Sexual side-effects of antipsychotic medication: Evaluation and interventions
50. Sexual dysfunction in women using major tranquilizers
51. Psychiatric drugs and orgasm in the human female
52. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: Frequency and etiology
53. A literature review of prolactin in schizophrenia
54. Sexual disorders in nonacute psychiatric outpatients
55. Implications of not treating hyperprolactinaemia
56. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinaemia
57. Decreased bone mineral density in medicated psychiatric patients
58. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy
59. Osteopenia, pathological fractures and increased urinary calcium excretion in schizophrenic patients with polydipsia
60. Osteoporosis and schizophrenia: Can we limit the known risk factors?
61. Adverse effects of the atypical antipsychotics
62. Weight gain associated with conventional and newer antipsychotics: A meta-analysis
63. Review of quetiapine and its clinical applications in schizophrenia
64. The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients
65. The nature and prevalence of depression in chronic schizophrenic in-patients
66. Depression, attempted suicide and suicide in patients with chronic schizophrenia
67. Depot neuroleptics
68. Diagnosis of secondary depression in schizophrenia: Implications for DSM-IV
69. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
70. New atypical antipsychotic medications
71. Schizophrenics kill themselves too: A review of risk factors for suicide
72. Suicides in schizophrenics
73. Clinical management of clozapine patients in relation to efficacy and side effects
74. Schizophrenia
75. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates
76. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
77. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics
78. 123I-IBZM SPECT study
79. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life
80. Measuring quality of life in patients with schizophrenia
81. Sertindole decreases hospitalisation and improves the quality of life of schizophrenic patients
82. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders; quality of life and clinical outcomes of a randomized clinical trial
83. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
84. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: Are they 'stabilizer' rather than typical compounds?
85. Patient satisfaction and the acceptability of long-term treatment with quetiapine
86. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis
87. Veryhigh dose fluphenazine decanoate. A controlled trial in chronic schizophrenia
88. High dose flupenthixol decanoate in chronic schizophrenia
89. Evaluation of treatment resistant schizophrenia
90. Psychotherapy, medication combinations and compliance
91. Subjective experience of treatment, side-effects, mental state and quality of life in Chronic schizophrenic outpatients treated with depot neuroleptics
92. Compliance therapy: An intervention targeting insight and treatment adherence in psychotic patients
93. Compliance therapy in psychotic patients: Randomised controlled trial
94. Patient expectations: What do primary care patients want from the GP and how far does meeting expectation affect patient satisfaction?
95. Doctorpatient communication: A review of the literature
96. Recognition of depressed affect in hospitalized psychiatric patients: Staff and patient perceptions
97. Differences in self-reported and observed pleasure in depression and schizophrenia
98. Vergleich von Selbst- und Fremdbeurteilung bei schizophrenen Patienten
99. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
100. Depressive syndromes in schizophrenic patients after discharge from hospital
101. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
102. Subjective effects of neuroleptics predict compliance
103. Improvement of schizophrenic patients subjective well-being under atypical neuroleptics
104. ASC: The development of a tool to aid communication with patients receiving antipsychotic therapy
105. ASC in US clinical practice
106. ASC in clinical practice: The UK experience